FAQs:
Saroglitazar (Trade name: Lipaglyn) is a recent drug developed to treat both type 2 diabetes mellitus and dyslipidemia. It is a dual regulator that corrects the imbalance in both the lipid profile and glycaemic indices. Saroglitazar plays a crucial role in controlling lipid and lipoprotein metabolism, glucose homeostasis, and inflammatory processes. This drug has an excellent clinical safety profile and higher efficacy in optimizing lipid and glycaemic targets.
What are the uses of Saroglitazar?
Saroglitazar uses lies in treating major conditions like:
– Diabetic dyslipidemia (high cholesterol in diabetes).
– Hypertriglyceridemia with type 2 diabetes mellitus uncontrolled by statin therapy.
– Non-alcoholic fatty liver disease
– It lowers ‘bad’ cholesterol and fats (such as LDL, triglycerides).
– It raises ‘good’ cholesterol levels (HDL).
The drug has also shown promising anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients.
What are the side effects of Saroglitazar?
Saroglitazar does not usually create many side effects with the recommended dosage. Common side effects are:
– Gastritis.
– Asthenia (lack of energy).
– Pyrexia.
– Severe sweating and headache.
– Dizziness.
– Chest discomfort.
1. Is Saroglitazar safe?
Saroglitazar is generally a safe and well-tolerated drug. No severe adverse reactions were reported in Saroglitazar treatment. Overall there is no safety concern with the use of this drug. Use this drug as recommended by your consulting physician.
2. When to take Lipaglyn Saroglitazar?
The recommended dose of Lipaglyn-Saroglitazar is one tablet of 4 mg or 2mg once a day. Lipaglyn is available as uncoated tablets for oral administration. Each uncoated tablet of lipaglyn contains 4 mg of Saroglitazar.
4. Will Saroglitazar tablets control Triglycerides?
Yes, Saroglitazar helps in the management of high cholesterol, especially triglycerides. It can lower the high blood triglycerides and improve insulin resistance.
5. Is Saroglitazar a statin?
No, Saroglitazar is not a statin. It is a non-statin drug approved for treating high triglycerides, type 2 diabetes mellitus, and dyslipidemia. They are the new generation of dual-action PPARs that provide a new approach to diabetes care, addressing hyperglycemia, dyslipidemia, and other metabolic syndromes. Saroglitazar is highly recommended for the treatment of diabetes dyslipidemia which couldn’t manage statin therapy.
6. Can Saroglitazar cause hypoglycemia?
Generally, Saroglitazar does not cause hypoglycemia. But in some patients, there may be hypoglycemic episodes where the patient needs to adjust the daily insulin dose with a consulting physician’s help. Gradually the patient will be stable with controlled glycemic parameters.
7. Does Saroglitazar cause weight loss?
One can observe a slight decrease in body weight when under the treatment of Saroglitazar. An average 1.5 to 3 kg weight loss is observed when using Saroglitazar for 6-months. Likely, the amount of weight one loses is low and varies from person to person. If you experience drastic weight loss, please consult your physician. Patients who experience a rapid decrease in weight should immediately consult a physician.
9. Is Saroglitazar a steroid?
No, Saroglitazar is not a steroid. Saroglitazar is a novel dual PPAR α/γ agonist, non thiazolidinediones (TZD) and non-fibric acid derivative, with a predominant PPAR α agonistic activity, which helps in controlling the blood glucose and lipid parameters.
10. Is Saroglitazar bad for kidneys?
Saroglitazar generally does not cause kidney damage. Clinical studies with Saroglitazar have not demonstrated any potential harm to renal function. But as a precaution, Saroglitazar treatment should be initiated with caution in patients with abnormal renal function.
Need more information on your treatment?
Submit a medical inquiry for personalized advice.
Side Effects:
– Asthenia (lack of energy).
– Pyrexia.
– Severe sweating and headache.
– Dizziness.
– Chest discomfort.
References:
More about Saroglitazar:
The drug has also shown promising anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients.